Amgen Inc.
DOSING REGIMEN FOR BCMA-CD3 BISPECIFIC ANTIBODIES

Abstract:

The present disclosure relates to an antibody construct comprising a first domain which binds to BCMA and a second domain which binds to CD3, for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the antibody construct is administered at a specified dose in at least one cycle, wherein one cycle comprises a specified period of administration of the antibody construct. Moreover, the disclosure relates to a method for the treatment of a BCMA positive neoplasm comprising administering a specified amount of such antibody construct, and the use of such antibody construct for the manufacture of a medicament for the treatment of a BCMA positive neoplasm.